Pneumonia clinical trials at UC Irvine

3 in progress, 0 open to eligible people

Showing trials for

  • Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19

    Sorry, in progress, not accepting new patients

    This study is a Phase 1 / 2 trial to determine the safety and efficacy of CYNK-001, an immunotherapy containing Natural Killer (NK) cells derived from human placental CD34+ cells and culture-expanded, in patients with moderate COVID-19 disease.

    Irvine, California and other locations

  • Reparixin as add-on Therapy to Standard of Care to Limit Disease Progression in Adult Patients With COVID-19 and Other Community-Acquired Pneumonia.

    Sorry, not currently recruiting here

    Primary objective: - To evaluate the efficacy of oral reparixin versus standard care alone in limiting disease progression in adult patients hospitalised for infectious pneumonia acquired in the community (CAP), including COVID-19. Secondary objectives: - To determine the effect of reparixin on several disease severity/progression measures including recovery, ventilatory free days and mortality. Safety objectives: - To evaluate the safety of oral reparixin versus placebo in the specific clinical setting.

    Orange, California and other locations

  • The INSPIRE-ASP PNA Trial

    Sorry, in progress, not accepting new patients

    The INSPIRE-ASP PNA trial is a cluster-randomized controlled trial of HCA hospitals comparing routine empiric antibiotic stewardship practices with real-time precision medicine computerized physician order entry smart prompts providing the probability that a non-critically ill adult admitted with PNA is infected with a resistant pathogen. Note: that enrolled "subjects" represents 59 individual HCA hospitals that have been randomized.

    Riverside, California and other locations

Our lead scientists for Pneumonia research studies include .

Last updated: